Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CiToxLAB Appoints John C. Kapeghian as Senior Director of Toxicology

Published: Wednesday, March 19, 2014
Last Updated: Tuesday, March 18, 2014
Bookmark and Share
This appointment makes the Montreal site attractive to North American clients and boosts CiToxLAB’s expertise in preclinical development and regulatory affairs.

CiToxLAB has announced that John C. Kapeghian has joined the company as senior director of toxicology in North America (Montreal, Canada).

His experience includes thirty years in preclinical drug safety at Ciba Pharmaceuticals (now Novartis) and Charles River Laboratories.

John is a renowned regulatory toxicologist. He brings outstanding expertise to the team at CiToxLAB. His skill set includes study design and implementation, data evaluation and report review, FDA pre-IND meeting representation and briefing document preparation, as well as Investigator Brochure and IND/NDA/BLA preparation.

John has a PhD in pharmacology/toxicology and is a diplomate of the American Board of Toxicology (DABT). He was formerly head of Experimental Toxicology at Ciba Pharmaceuticals (now Novartis) and then joined Charles River Laboratories where he established and led the Navigator Scientific and Regulatory Consulting Group and Program Management Team.

As the president of Preclinical Safety Associates, he has recently collaborated with pharmaceutical and biotechnology companies worldwide to advise on programs, study design and to monitor non-clinical regulatory packages.

John is a member of the Society of Toxicology and the American College of Toxicology. He sat on the editorial board of the International Journal of Toxicology.

Over the years, he has published dozens of peer-reviewed papers and continues to be active in his areas of specialty, including biotechnology-derived therapeutics development and drug-induced hepatotoxicity.

John frequently presents his work at international scientific meetings and sponsors and organizes preclinical training workshops, including study director training.

“I am delighted that we are adding a colleague of this standing to our organization. John will make a valuable contribution to our customers’ development programs. John’s recruitment reflects the CiToxLAB policy of carefully listening to our customers’ needs,” said Dr Jean-Francois Le Bigot, chairman and CEO of the CiToxLAB Group.

“CiToxLAB will celebrate its 45th anniversary in 2014, just three years after CIT merged with LAB-Research. CiToxLAB continuously invests in new techniques to validate in vivo and in vitro models. New safety pharmacology models have been recently implemented in NHPs and minipigs. We also invested in new methods for biomarkers in genomics, flow cytometry and immunohistochemistry. The hiring of John C. Kapeghian will make our Montreal site even more attractive for our clients in North America and reflects our mission to make CiToxLAB a science-driven CRO that offers the best scientific expertise to customers,” said Dr. Le Bigot.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CiToxLAB Announces the Appointment of Dr. Philippe Ancian as Senior Director
This appointment will allow to drive current and future developments at CiToxLAB’s European and North American sites in the area of preclinical and clinical biomarkers, which is currently experiencing strong growth.
Wednesday, January 14, 2015
CiToxLAB Group Increases Revenue by 25 Per Cent over Full Year of 2012
Despite a stuttering outsourced preclinical development market, the global expansion of the CiToxLAB Group has attracted more clients.
Thursday, February 21, 2013
CiToxLAB Group Announces a 34 Per Cent Revenue Increase for the First Half of 2012
One year after merger of France-based pre-clinical research organization, CIT, and Canada’s LAB-Research, the new group posts consolidated H1 revenues of EUR 37.2 million (USD 48.4 million).
Thursday, October 04, 2012
CiToxLAB Increases Inhalation Test Capabilities in North America and Europe
Growth in capacity and capabilities sees CiToxLAB emerge as a major player in the safety assessment of pharmaceuticals and chemicals via the inhalation route.
Friday, March 09, 2012
CiToxLAB Appoints Paul C. Barrow as Director of Scientific Projects and Client Consulting
This appointment will increase CiToxLAB’s capabilities in reprotoxicology and juvenile studies.
Thursday, June 30, 2011
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!